Enterprise Therapeutics, Science Park Square, Brighton BN1 9SB, UK.
Int J Mol Sci. 2020 Mar 30;21(7):2386. doi: 10.3390/ijms21072386.
The concept that increasing airway hydration leads to improvements in mucus clearance and lung function in cystic fibrosis has been clinically validated with osmotic agents such as hypertonic saline and more convincingly with cystic fibrosis transmembrane conductance regulator (CFTR) repair therapies. Although rapidly becoming the standard of care in cystic fibrosis (CF), current CFTR modulators do not treat all patients nor do they restore the rate of decline in lung function to normal levels. As such, novel approaches are still required to ensure all with CF have effective therapies. Although CFTR plays a fundamental role in the regulation of fluid secretion across the airway mucosa, there are other ion channels and transporters that represent viable targets for future therapeutics. In this review article we will summarise the current progress with CFTR-independent approaches to restoring mucosal hydration, including epithelial sodium channel (ENaC) blockade and modulators of SLC26A9. A particular emphasis is given to modulation of the airway epithelial calcium-activated chloride channel (CaCC), TMEM16A, as there is controversy regarding whether it should be positively or negatively modulated. This is discussed in light of a recent report describing for the first time bona fide TMEM16A potentiators and their positive effects upon epithelial fluid secretion and mucus clearance.
增加气道水合作用可改善囊性纤维化患者的黏液清除和肺功能,这一概念已通过渗透压剂(如高渗盐水)得到临床验证,通过囊性纤维化跨膜电导调节因子(CFTR)修复疗法得到更有力的验证。虽然 CFTR 调节剂已迅速成为囊性纤维化(CF)的标准治疗方法,但目前的 CFTR 调节剂并非对所有患者都有效,也无法将肺功能下降速度恢复到正常水平。因此,仍需要新的方法来确保所有 CF 患者都能获得有效的治疗。尽管 CFTR 在调节气道黏膜的液体分泌方面起着至关重要的作用,但还有其他离子通道和转运蛋白是未来治疗的可行靶点。在这篇综述文章中,我们将总结目前在不依赖 CFTR 的基础上恢复黏膜水合作用的方法,包括上皮钠离子通道(ENaC)阻断剂和 SLC26A9 调节剂。特别强调气道上皮钙激活氯离子通道(CaCC)、TMEM16A 的调节,因为对于 CaCC 是正向调节还是负向调节存在争议。这一点是根据最近的一份报告讨论的,该报告首次描述了真正的 TMEM16A 增强剂及其对上皮液分泌和黏液清除的积极影响。